Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nurix Therapeutics, Inc.
University of Oklahoma
Baylor College of Medicine
Hutchmed
St. Jude Children's Research Hospital
Indiana University
Medical College of Wisconsin
Umoja Biopharma
Children's Hospital of Philadelphia
Seattle Children's Hospital
Fate Therapeutics
University of Arizona
University College, London
Ohio State University Comprehensive Cancer Center
University of Alabama at Birmingham
Institute of Hematology & Blood Diseases Hospital, China
Stanford University
University Hospital Tuebingen
Institute of Hematology & Blood Diseases Hospital, China
University Health Network, Toronto
Memorial Sloan Kettering Cancer Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Thomas Jefferson University
Stanford University
Hangzhou Sumgen Biotech Co., Ltd.
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Ono Pharmaceutical Co. Ltd
Dana-Farber Cancer Institute
Daiichi Sankyo
Kymera Therapeutics, Inc.
Boehringer Ingelheim
Massachusetts General Hospital
Beijing Boren Hospital
Cedars-Sinai Medical Center
BeiGene
Servier
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Pfizer
OrphAI Therapeutics
Kyowa Kirin Co., Ltd.
Virginia Commonwealth University
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
Fate Therapeutics